• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Veracyte, Inc. - Common Stock (NQ:VCYT)

46.32 -13.46 (-22.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,994,804
Open 48.77
Bid (Size) 44.75 (100)
Ask (Size) 46.33 (500)
Prev. Close 59.78
Today's Range 43.52 - 50.17
52wk Range 22.92 - 60.91
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Veracyte Q2 Earnings Call Highlights ↗
July 31, 2026
Veracyte (NASDAQ:VCYT) reported second-quarter 2026 revenue growth of 15% and raised its full-year revenue outlook, while highlighting the launches of its Prosigna LDT breast cancer test and TrueMRD... 
Via MarketBeat
Topics Earnings
Veracyte (NASDAQ:VCYT) Smashes Q2 Estimates but Full-Year Guidance Disappoints, Shares Fall ↗
July 30, 2026
Via Chartmill

Performance

YTD
+9.3%
+9.3%
1 Month
-22.6%
-22.6%
3 Month
+40.0%
+40.0%
6 Month
+21.6%
+21.6%
1 Year
+97.0%
+97.0%

More News

Read More
News headline image
Veracyte Announces Second Quarter 2026 Financial Results
July 30, 2026
From Veracyte, Inc.
Via GlobeNewswire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
July 28, 2026
From Veracyte, Inc.
Via GlobeNewswire
Veracyte Inc (NASDAQ:VCYT) Shows a High Growth Momentum Breakout Setup Near Resistance ↗
July 24, 2026
Via Chartmill
Veracyte Inc (NASDAQ:VCYT): A High Growth Stock With a Strong Technical Breakout Setup ↗
July 21, 2026
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Fits the Affordable Growth Profile ↗
July 06, 2026
Via Chartmill
High Growth Momentum Breakout Setup: Veracyte Inc (NASDAQ:VCYT) ↗
June 16, 2026
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) Smashes Q1 Estimates and Raises Full-Year Guidance, Shares Surge ↗
May 05, 2026
Via Chartmill
Veracyte Inc (NASDAQ:VCYT) GARP Analysis Reveals Strong Growth at a Reasonable Price ↗
May 02, 2026
Via Chartmill
News headline image
Veracyte to Release Second Quarter 2026 Financial Results on July 30, 2026
July 09, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
A Veracyte Insider Sold 24,000 Company Shares for $1.1 Million. Here's a Deeper Look at the Transaction. ↗
July 04, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally ↗
June 27, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Veracyte Announces Commercial Launch of the Prosigna Breast Test in the U.S.
June 01, 2026
From Veracyte
Via Business Wire
News headline image
ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
May 30, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Landmark OPTIMA Trial Delivers Practice-Changing Evidence that Veracyte’s Prosigna Test Identifies Patients with High-Risk Breast Cancer Who Can Safely Avoid Chemotherapy
May 29, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte to Host Investor Call on June 1, 2026 to Discuss ASCO Findings
May 22, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
OPTIMA Trial Results to Be Presented at ASCO Provide New Evidence Supporting Prosigna-Guided Chemotherapy Decisions in Breast Cancer
May 21, 2026
From Veracyte
Via Business Wire
News headline image
Veracyte to Participate in Upcoming Investor Conferences
May 19, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
May 15, 2026
From Veracyte, Inc.
Via Business Wire
News headline image
A Toronto AI-Cardiac Diagnostics Company Just Cleared Three of the Hardest Validation Bars in Medtech
May 13, 2026
From USA News Group
Via GlobeNewswire
News headline image
Why Veracyte Stock Is Skyrocketing Higher This Week ↗
May 08, 2026
Via The Motley Fool
News headline image
Veracyte (VCYT) Q1 2026 Earnings Transcript ↗
May 05, 2026
Via The Motley Fool
Get insights into the top gainers and losers of Tuesday's after-hours session. ↗
May 05, 2026
Via Chartmill
News headline image
Veracyte Announces First Quarter 2026 Financial Results
May 05, 2026
From Veracyte, Inc.
Via Business Wire

Frequently Asked Questions

Is Veracyte, Inc. - Common Stock publicly traded?
Yes, Veracyte, Inc. - Common Stock is publicly traded.
What exchange does Veracyte, Inc. - Common Stock trade on?
Veracyte, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Veracyte, Inc. - Common Stock?
The ticker symbol for Veracyte, Inc. - Common Stock is VCYT on the Nasdaq Stock Market
What is the current price of Veracyte, Inc. - Common Stock?
The current price of Veracyte, Inc. - Common Stock is 46.32
When was Veracyte, Inc. - Common Stock last traded?
The last trade of Veracyte, Inc. - Common Stock was at 07/31/26 04:00 PM ET
What is the market capitalization of Veracyte, Inc. - Common Stock?
The market capitalization of Veracyte, Inc. - Common Stock is 3.13B
How many shares of Veracyte, Inc. - Common Stock are outstanding?
Veracyte, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap